Trends in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Seroprevalence in Massachusetts Estimated from Newborn Screening Specimens신생아 선별 검체에서 추정한 매사추세츠 주의 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2) 혈청 유병률의 추세Article Published on 2022-08-242022-09-12 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 진단, [키워드] acute respiratory syndrome analyzed antibody Bayesian black collected Community Concordance coronavirus coronavirus 2 cumulative cumulative incidence diagnostic estimate Estimated fraction higher odd highest identify incidence increase in Massachusett Massachusetts Maternal maternal antibody Newborn newborn screening Protective public health reported representing respiratory retrospective risk SARS-CoV-2 SARS-CoV-2 transmission Screening Seroprevalence seroprevalence. specificity specimen Surveillance susceptible sustained Transmission trend widespread [DOI] 10.1093/cid/ciac158 PMC 바로가기 [Article Type] Article
Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes심각한 COVID-19 결과를 예방하는 REGEN-COV 항체 조합의 효과Article Published on 2022-08-022022-09-11 Journal: Nature Communications [Category] SARS, 변종, 임상, 진단, 치료법, [키워드] 95% CI antibody combination approved Casirivimab Clinical characteristics Combination COVID-19 COVID-19 hospitalization COVID-19 patients death defined delta variant demographic demographic and clinical characteristics determine Diagnosis effective Effectiveness Estimated FIVE hazard ratio healthcare high-risk patient High-risk patients Hospitalization Imdevimab infected with SARS-CoV-2 monoclonal antibodies monoclonal antibody outcome Patient performed reducing REGEN-COV Repository retrospective cohort study risk severe COVID-19 severe disease treated Treatment Treatment effectiveness used data were used [DOI] 10.1038/s41467-022-32253-9 PMC 바로가기 [Article Type] Article
Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in SingaporeArticle Published on 2022-08-012022-11-16 Journal: JAMA Network Open [Category] SARS, 변종, [키워드] 95% CI adjusted Against age Assessing BBIBP-CorV BNT162b2 booster cohort study Combination combinations CoronaVac COVID-19 COVID-19 vaccination death defined determine dose Effectiveness eligible Estimated greater homologous inactivated individual Infection intensive care Moderna mRNA mRNA COVID-19 vaccine mRNA vaccine mRNA-1273 no significant difference Older omicron outcome Pfizer-BioNTech provided reduction Reinfection SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 variant severe COVID-19 severe disease Sex Singapore Sinopharm Sinovac supplemental oxygen time interval vaccination Vaccine vaccine dose waned was determined were excluded women [DOI] 10.1001/jamanetworkopen.2022.28900 PMC 바로가기
Effectiveness and protection duration of Covid-19 vaccines and previous infection against any SARS-CoV-2 infection in young adults젊은 성인의 모든 SARS-CoV-2 감염에 대한 Covid-19 백신 및 이전 감염의 효과 및 보호 기간Article Published on 2022-07-082022-09-11 Journal: Nature Communications [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI Ad26 Ad26.COV2.S Adults B.1.617 BNT162b2 caused Community contribute COVID-19 vaccination COVID-19 vaccines decrease delta variant dominant dropped Effectiveness Estimated evaluate General population increase in infected individuals Infection mRNA mRNA vaccine mRNA-1273 offer provide repeated SARS-COV-2 infection SARS-CoV-2 variant Spread surveillance testing vaccinated individual vaccinated individuals vaccination Vaccine variant while [DOI] 10.1038/s41467-022-31469-z PMC 바로가기 [Article Type] Article
Association of Blood Viscosity With Mortality Among Patients Hospitalized With COVID-19Research article Published on 2022-07-012022-10-05 Journal: Journal of the American College of Cardiology [Category] 바이오마커, [키워드] adjusted age association baseline Blood Blood viscosity calculated cardiovascular disease cardiovascular risk characterized clinically Comorbidities Comorbidity contribute covariate COVID-19 Cox proportional hazard death determine Endothelial dysfunction Estimated evaluate evaluated highest hospitalized COVID-19 patient hospitalized COVID-19 patients immune response in-hospital mortality increase in increases in inflammatory biomarkers lowest Mortality Mount Sinai multivariate objective outcome participant Patient patients hospitalized quartile reducing Result rheology epidemiology Sex significantly Stage study population subgroups System Thrombotic complications viscosity were used with COVID-19 [DOI] 10.1016/j.jacc.2022.04.060 [Article Type] Research article
Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study중증 COVID-19에 대한 회복기 혈장의 안전성 및 효능: 무작위, 단일 맹검, 병렬, 대조 임상 연구Randomized Controlled Trial Published on 2022-06-272022-09-11 Journal: BMC Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 95% CI adjusted Admission anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 S1 IgG antibodies antibody antibody levels assigned benefit blinded clinical clinical study clinical trial conducted controlled clinical study convalescent plasma coronavirus disease Coronavirus disease 2019 COVID-19 CP plus standard therapy discharge dose early stage early stages Efficacy Estimated evaluate evaluated Follow-up hospital Hospitalization IgA IgA antibodies IgA antibody IgG increase in intensive care intensive care unit admission less mechanical ventilation Mortality MOST pandemic participant Patient patients per-protocol analysis plasma Primary outcome Primary outcomes Randomized receive reduce reduction reduction in S1 IgG Safe Safety SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2. secondary outcome Secondary outcomes Seven severe coronavirus disease severe COVID-19 ST alone ST group Standard therapy symptoms onset the disease the SARS-CoV-2 the WHO therapeutic option titers transfused transfused plasma transfusion treat Variability variant Viral Viral load viral load reduction was obtained [DOI] 10.1186/s12879-022-07560-7 PMC 바로가기 [Article Type] Randomized Controlled Trial
Evaluation of a Wastewater-Based Epidemiological Approach to Estimate the Prevalence of SARS-CoV-2 Infections and the Detection of Viral Variants in Disparate Oregon Communities at City and Neighborhood ScalesSARS-CoV-2 감염의 유병률을 추정하기 위한 폐수 기반 역학 접근 방식 평가 및 도시 및 인근 지역 규모의 이질적인 오레곤 커뮤니티에서 바이러스 변이체 감지Article Published on 2022-06-012022-09-11 Journal: Environmental health perspectives [Category] COVID19(2023년), SARS, 변종, 치료기술, [키워드] addition Affect analysis Asymptomatic Asymptomatic cases authority B.1 city clinically communicable Community Concentration correlated correlation COVID-19 demography detection disease disparate door eight Epidemiology estimate Estimated event examined greater Health authority hotspot identify indicated Infection infections location log nasal swab neighborhood Pearson positive positive correlations Prevalence Previous studies previous study public health quantified Quantitative R 2 Randomized ranged reliability reported SARS-CoV-2 SARS-CoV-2 RNA SARS-CoV-2 variant SARS-CoV-2 variants scalability scale sequenced significantly Surveillance tested Treatment Variation variations wastewater [DOI] 10.1289/EHP10289 PMC 바로가기 [Article Type] Article
Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age6~11세 어린이의 mRNA-1273 Covid-19 백신 평가Clinical Trial Published on 2022-05-112022-09-25 Journal: The New England Journal of Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료법, [키워드] 95% CI 95% confidence interval acute respiratory syndrome Administered Adults age Analysis assigned authority B.1.617.2 children circulating coronavirus coronavirus disease criterion development dominant dose effective Efficacy Estimated events fatigue groups headache immune response incidence Infection Inflammatory injection Injection-site pain Interim interquartile range median mRNA-1273 mRNA-1273 vaccine myocarditis Neutralizing antibody titer observer-blinded open label Part participant phase 2–3 trial phase 3 trial Placebo placebo-controlled Prevent public health Randomly receive reported response Result Safe Secondary objective selected Serious Adverse Events Serologic response Symptoms syndrome the vaccine transient adverse Trial Vaccine variant was selected Year [DOI] 10.1056/NEJMoa2203315 PMC 바로가기 [Article Type] Clinical Trial
A parallel randomised controlled trial of the Hypoglycaemia Awareness Restoration Programme for adults with type 1 diabetes and problematic hypoglycaemia despite optimised self-care (HARPdoc) Research Published on 2022-04-282022-10-05 Journal: Nature Communications [Category] 임상, [키워드] Analysis Anxiety Attitude avoidance Awareness baseline blinded changes in cognitive conducted Depression diabete difference distress effective emotional Estimated Health Hypothesis Impaired insulin Measures outcome positive Primary outcome randomised randomised controlled trial rate ratio recall reduced reducing restoration risk secondary self-care significantly T1D Treatment Trial Two-arm [DOI] 10.1038/s41467-022-29488-x [Article Type] Research
Estimating excess visual loss from neovascular age-related macular degeneration in the UK during the COVID-19 pandemic: a retrospective clinical audit and simulation modelCOVID-19 전염병 동안 영국에서 신생혈관 연령 관련 황반변성으로 인한 과도한 시각 손실 추정: 후향적 임상 감사 및 시뮬레이션 모델Article Published on 2022-04-152022-09-12 Journal: BMJ Open [Category] 진단, [키워드] Age-related macular degeneration average bootstrap COVID-19 COVID-19 pandemic dataset decrease driving dropped electronic medical record Estimated eye hypothetical increase in incrementally lockdown Multiple National Health Service NHS ophthalmology outcome outcomes proportion public health public health. reduced reduction in retrospective risk stratified suggested Treatment Trust visual acuity visual loss worsened [DOI] 10.1136/bmjopen-2021-057269 PMC 바로가기 [Article Type] Article